Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Phospholipid drug conjugate therapies

Jarrod Longcor • 28 Sep 2019
ESMO 2019
General

Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, outlines the current focus on phospholipid drug conjugate (PDCs), specifically CLR131, and what the future holds for this line of therapy at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Jarrod Longcor

1:15
R/R DLBCL challanges: novel therapeutics
Jarrod Longcor • 28 Sep 2019
1:22
Jarrod Longcor: ESMO highlights
Jarrod Longcor • 28 Sep 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals